The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture.
about
Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implicationsLupus nephritis: the evolving role of novel therapeuticsSmall molecules in the treatment of systemic lupus erythematosusEmerging therapies for systemic lupus erythematosus--focus on targeting interferon-alphaProteasome inhibition prolongs survival during lethal hemorrhagic shock in ratsCD163+ M2c-like macrophages predominate in renal biopsies from patients with lupus nephritis.The ubiquitin-proteasome system and microvascular complications of diabetesBortezomib followed by autologous stem cell transplantation in a patient with rheumatoid arthritis: A case report and review of the literature.New approaches for the treatment of lupus nephritis in the 21st century: from the laboratory to the clinic.Targeting B cells and autoantibodies in the therapy of autoimmune diseases.B cells biology in systemic lupus erythematosus-from bench to bedside.Lupus nephritis and B-cell targeting therapy.Current and Emerging Therapies for Lupus Nephritis.Cell death and cytokine production induced by autoimmunogenic hydrocarbon oils.Bortezomib-induced acute interstitial nephritis.Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity.Which B-cell subset should we target in lupus?Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease.
P2860
Q26775756-38FCA84A-91A8-4752-ACB6-AB19FA68E25BQ26998390-158B8733-0D4B-465C-95BF-2FD98AD3C29BQ27010090-19045E2B-EB08-4B13-AA10-F0C1EEF4A29DQ28265144-F93199B2-5F0E-4FB3-ADE6-33F9DB18F6CCQ34279164-29E82AF7-E353-4302-875B-3C9D5652FA91Q35993141-FDAE000B-C770-48F0-B8E4-32AD064E6565Q37369903-9E1E1EB2-376E-4ACB-A79D-BFBC565BACFFQ37552226-F37395D9-4A80-4D57-AB2A-9DBABD15D898Q38148585-15FCACB2-36BD-4496-92D1-A2CDACF25A7DQ38207937-69F8882A-1204-4090-89AA-C0D377CC9C3BQ38631964-C0F00C59-21B4-4B08-857A-8CA8A3AD5E93Q38643755-9EBB327F-06D9-4BA6-B380-7AC2FAD01A13Q38855495-9CC65EFB-CC3A-4C7E-9C27-14E3888DF0DAQ39292218-6DC548D6-CDDD-4D30-BC22-6C5938734099Q41141007-CF6D1469-6227-47AC-BC8A-41F216E2F5A1Q41363502-EEA24A6F-88A9-455A-801C-02DA16EDDD2CQ46005728-3D7873FA-88EE-4B5C-BF0E-19799DA1D1E4Q47548339-89BC712B-D118-41FF-A276-72502AE451DB
P2860
The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
The proteasome inhibitor borte ...... bulointerstitial architecture.
@en
The proteasome inhibitor borte ...... bulointerstitial architecture.
@nl
type
label
The proteasome inhibitor borte ...... bulointerstitial architecture.
@en
The proteasome inhibitor borte ...... bulointerstitial architecture.
@nl
prefLabel
The proteasome inhibitor borte ...... bulointerstitial architecture.
@en
The proteasome inhibitor borte ...... bulointerstitial architecture.
@nl
P2093
P2860
P356
P1433
P1476
The proteasome inhibitor borte ...... bulointerstitial architecture.
@en
P2093
Kerstin Amann
Kerstin Benz
Kirsten Neubert
Michael Wiesener
Nadine Hainz
Reinhard E Voll
Silke Meister
Susanne Thomas
P2860
P304
P356
10.1159/000334955
P577
2012-01-26T00:00:00Z